Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs, specialized in T-cell receptor (TCR) engineering and analysis, now offers a tailor-made solution to assist customers in performing the assessment of TCR clonality quantitation and CDR3 size diversity.
T-cells are a subset of lymphocytes that are the primary mediators of cellular immunity in humans and animals. TCR is a complex of integral membrane proteins that participate in the activation of T lymphocytes in response to an antigen. TCRs, containing α-chain and β-chain, are encoded by multiple gene segments that rearrange during T-cell development and generate most of the antigen receptor diversity. For example, the human TCR β-chain gene complex includes at least 57 variable (V) gene segments, 2 diversity gene segments, 13 joining gene segments, and 2 consistent gene segments which group into 24. Both the TCR α-chain and β-chain have three hypervariable or complementarity determining regions (CDRs) and the CDR3 is the main CDR responsible for recognizing processed antigen, the diversity of which in TCR Vβ is a consequence of different V, D, J recombinations. Determination of TCR repertoire diversity (clonality) within CDR3 region can serve as a tool to study varieties of diseases related to immune-mediated disorders ,such as autoimmune diseases, cancers, immunization of vaccine and bone marrow transplantation. In addition, molecular analysis of TCR repertoire clonality within CDR3 region can be used as a monitoring tool in tracking curative effects of antiviral or anti-tumor treatments. Multiple molecular analysis technologies of Creative Biolabs has been elaborately integrated for providing customers an expecting analytical platform of TCR clonality quantitation and CDR3 size diversity. Our TCR clonality quantitation and CDR3 size diversity detection service including 22 classes of the Vα or Vβ T-cell receptor repertoire in mouse and 30 classes of Vα or Vβ repertoire in human. The whole platform of this service ranges from RNA purification, nested PCR, gene scanning technology service, statistical and quantitative analysis to CDR3 domain sequencing. Utilizing sophisticated analysis tools, we can guarantee you our data collection and analysis is rapid and accurate. Furthermore, the samples such as cell pellets, total RNA, cDNA, even whole blood are all acceptable. Creative Biolabs can design appropriate and detailed procedures according to your specific requirements.
Our sensitive and quantitative assessment can reveal any tiny differences in the diversity of human and mouse TCR Vα and Vβ repertoire.
To discuss your demands or to request a proposal, please contact us by .
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
